Q. Who can apply?
A. The Pfizer APEC Research Grants are awarded
for the purpose of furthering clinical research in the field of Paediatric Endocrinology
and associated areas. The proposals should involve clinical research.
The Pfizer APEC Research Grants program seeks to encourage medical graduates in
Australia who are early in their research career. Applications are invited from
medical graduates who have obtained specialist qualifications within the last five
years, or are currently in advanced training. Applications will also be considered
on a case by case basis from graduates returning to research after an appropriate
break.
The principal applicant must be a citizen or permanent resident of Australia, and
must be currently living in Australia. Grant recipients must conduct the majority
of the research within Australia.
Q. Amount and tenure of grants
A. Grants will be awarded for one year. Individual grants
will be up to AU$55,000 (including GST) per annum and will be awarded to cover part
salaries, equipment, research materials and expenses. Equipment will only be funded
if it is essential for the conduct of the research. Travel to conferences will only
be funded to the value of AU$1500.
Grant recipients must notify the APEC Research Secretariat of any other funding
obtained (or applied for) for the duration of the grant. Only one APEC Research
Grant will be allocated to a single applicant in a given year, although applications
will be accepted and reviewed for more than one project. Applicants will not be
eligible to receive funding from any other Pfizer Research Grants program in the
same financial year.
For the year 2008 the APEC Research Grants Program has been included on the Australian
Competitive Grants Register (ACGR), which contributes the income portion of the
DETYA Higher Education Research Data Collection.
Q. GST
A. Your application should include provision
for GST on the entire amount requested. If you are a successful applicant you will
be required to provide Pfizer Australia with a tax invoice inclusive of GST from
your institution. This tax invoice must include the institution’s ABN.
Q. Adjudication process
A. Applications will initially be assessed for
completeness. Incomplete applications will not be processed further.
Applications will be reviewed by two independent reviewers and by the Australian
Physicians Independent Committee (APIC), which is composed of leading physicians
and researchers from around the country. Pfizer Head Office in New York will also
review proposals involving any Pfizer compounds. The APIC is responsible for independent
objective evaluation and recommendations of funding proposals for research projects.
All decisions of the APIC are final and no correspondence will be entered into.
If a grant is successful and Pfizer medicines or active substances are listed in
the proposal, the supply of these drugs would be subject to normal company approval
procedures for investigator initiated research grants.
Q. Members of the Australia Paediatric
Endocrine Care Grants Australian Physicians Independent Committee (APIC).
A. In 2007, the APIC comprises a core committee
of two members:
A/Professor Christopher Cowell, The Children’s Hospital, Westmead, NSW (Chair)
Professor George Werther, Royal Children’s Hospital, VIC
Working closely with the core committee is the Advisory Panel, which is composed
of the following leading physicians and researchers from around Australia:
Dr Timothy Jones, Princess Margaret Hospital, WA
Dr Christine Rodda, Monash Medical Centre, VIC
Professor Ken Ho, Garvan Institute, NSW
Administrative support will be provided by the APEC Research Grants Secretariat,
which is comprised of medical/scientific staff from Pfizer Australia.
Q. Privacy of personal information
A. All personal information provided in your
application, project summary and assessment details will be kept by the APEC Research
Grants Secretariat, Pfizer Australia Pty Ltd and used only for the purposes of administering
this application, and, if successful, the grant. Your personal information will
be disclosed to reviewers as noted above. You have the right to access your personal
information at any time. If you wish to do this, please contact Pfizer Australia
using the details provided on the ‘Contact us’ page.
Q. Your application
A. If you have any questions regarding the completion
of the application form please contact the APEC Research Grants Secretariat.
The application and attachments indicated must be presented on the APEC Research
Grants application form which can be obtained from the “How to Apply” page.
Applicants are required to complete their applications electronically in a minimum
size of 12-point font; using the template provided. Please provide one original
(printed single sided) and three hard copies, which may be double sided and an electronic
version of the application and your CV (Microsoft Word format) either on a disc
or via email.
Send the completed application to:
Ms Kathryn Watts
Secretariat
Pfizer Australia APEC Research Grants (Pfizer Australia)
38-42 Wharf Road
West Ryde NSW 2114
Contact details:
Phone: (02) 9850 3771
Email: apecgrants@pfizer.com
Fax: (02) 9850 3131
Required documents
Applicants must supply one original and three hard copies of each of the following:
• Completed APEC Research Grants application form with original signatures in Sections
F, G and H.
• Study proposal
• CV (principal investigator only)
• Publication list
• Human Research Ethics Committee approval letter, if applicable. Funding will not
be granted until the ethics approval letter has been received by the APEC Research
Grants Secretariat.
• A letter from the supervisor or department head supporting the project.
Q. Conditions
A. Successful applicants of grants involving
the use of Pfizer compounds provided by Pfizer will be required to sign a Research Grants Agreement.
The agreement conveys certain intellectual property and commercial use access rights
only when research involves a Pfizer compound.
The APEC Research Grants are awarded with the expectation that timely submissions
for presentation will be made at appropriate medical meetings or research forums
and that abstracts or papers will be submitted for publication in appropriate peer-reviewed medical
journals. A copy of all published papers must be sent to the APEC Research Grants
Secretariat. Furthermore, Pfizer Australia will be acknowledged for sponsoring the
APEC Research Grants.
It is a requirement of the APEC Research Grants that protocols that receive funding
are not significantly altered following the review process. It is expected that
the secretariat will be formally notified of substantial changes.
Twelve months after receiving funds, grant recipients will be required to provide
a 500-word research summary to the APEC Research Grants Secretariat. In addition,
the grant recipients will be required to provide Pfizer with an opportunity to review
any proposed publications involving a Pfizer product.
Pfizer Australia reserves the right to publicise the names of the grant recipients,
their institutions, titles and summaries of their research projects, following consultation
with the APIC.
The funding is not being used to influence or reward the recipient for present,
past or future use or support of Pfizer medicines or to influence the outcome of
clinical trials.
All decisions of the APIC are final.
Closing date for applications is 30 May 2008.
|